@article{cfbcaa2b4db84f798a90a8bee885447f,
title = "SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)",
author = "Guillermo Garcia-Manero and Megan Othus and Pagel, \{John M.\} and Radich, \{Jerald P.\} and Min Fang and Rizzieri, \{David A\} and Guido Marcucci and Strickland, \{Stephen A.\} and Mark Litzow and Savoie, \{Mary Lynn\} and Medeiros, \{Bruno C.\} and Sekeres, \{Mikkael A.\} and Lin, \{Tara L.\} and Uy, \{Geoffrey L.\} and Powell, \{Bayard L\} and Kolitz, \{Jonathan E.\} and Larson, \{Richard A.\} and Stone, \{Richard M.\} and Claxton, \{David F.\} and James Essell and Selina Luger and Mohan, \{Sanjay R.\} and Anna Moseley and Appelbaum, \{Frederick R.\} and Erba, \{Harry P.\}",
note = "Graphic][1] Background: A majority of younger pts with AML receive initial therapy with a 7+3 scheme. Escalated doses of daunorubicin (dauno) in combination with standard doses of ara-C may lead to improved outcomes (Fernandez; NEJM 2009).",
year = "2016",
month = dec,
day = "2",
language = "American English",
volume = "128",
journal = "Blood",
}